newsfilter
← Latest News
Business Wire·

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of an end of Phase 1 (EOP1) meeting with the US Food